A New Approach to the Chronology of Biblical History from Abraham to Samuel.  112 pages. $29.95. Click for details. The Exodus Happened 2450 B.C.  94 pages. $29.95. Click for details. Noah Aging: Cause and Cure.  143 pages. Free download. Click for details. Click for a quick introduction to vitamin MePA. Click to purchase vitamin MePA. Click to give a gift of support.
  Advanced Search
Sign Up

  • Facebook, Instagram: @AgingCauseAndCure
  • Twitter: @AgingCauseCure



Biblical Chronology Dendrochronology Radiocarbon Dating     Mt. Sinai Jericho Ai The Exodus Noah's Ark Imhotep/Joseph Vitamin MePA

Contact Us

books newsletters time charts

Vitamin MePA Testimonials

Prostate Cancer

Theory suggests that vitamin MePA might be effective against cancer. MePA is the anti-aging vitamin. Cancer is mainly a disease of old age. Theory suggests that in the process of rolling back aging, the aging-related disease of cancer might also be rolled back. Here is the first pilot study addressed to this theoretical possibility.

by Thomas James Godfrey; October 1, 2017

The last chapter in Aging: Cause and Cure, by Dr. Gerald E. Aardsma, covers a personal testimonial of his experience with taking methylphosphonic acid (MePA) as well as that of his wife. They are the first two people known to have begun testing this experimental vitamin in modern times. I am the third. This is my own testimonial, submitted at his invitation. He invited me to participate in a trial when he found out that I have a medical condition that might be improved by taking MePA. Let me begin with some background. I hope it is not too boring.

In November 2013, a PSA (Prostate Specific Antigen) test result (9.3) and a digital rectal exam suggested that I might have prostate cancer. Later tests and consultations with specialists at the Duke Cancer Center in Durham, NC, confirmed this diagnosis. In particular, three of four targeted needle core biopsies on the left side of my prostate gland yielded a report of prostatic adenocarcinoma (prostate cancer), one with a Gleason score of 8, two with 6. No cancer was detected in any of the four other core biopsies, including all three taken on the right side. The "high grade" cancer found in my prostate gland was considered too pervasive and too aggressive to advise watchful waiting or any option for targeted treatment of only specific parts of the gland.

Therefore, on April 17, 2014, a robotic radical prostatectomy was performed on me at Duke as recommended. In less technical terms, my entire prostate gland was removed at this time, along with seminal vesicles and some nearby groups of lymph nodes. A nerve-sparing technique was used on the right side but not on the left side. The procedure was somewhat complicated, partly because my prostate was stuck to the front of a rectal wall. After the surgery, the removed items were examined to see whether any cancerous tissue was cut. Any cancer found at a cut would have meant that some cancer had been left behind in my body. No problem was found, and the Gleason score was revised down to 7. This was all good news, suggesting that I might be rid of prostate cancer.

On July 31 [data point 1 on the graph] and again on October 15, 2014 [point 2], I went back to Duke to have my PSA level checked. Both of these times, it was reported to be less than 0.01, which was considered undetectable PSA. This was good news too, because if PSA had been detected so long after the surgery, it would probably mean that some cancer cells had escaped the prostate and continued to produce PSA somewhere else in my body.

Unfortunately, this was not the end of the story. The next test on March 27, 2015 [point 3], showed that the level was up to 0.04, but this was still too low to cause concern. Similarly, even though the result of yet another test on March 7, 2016 [point 4], was 0.25, not even this level seemed particularly alarming to me. However, when the result of a test on April 7, 2017 [point 5] was 1.6, I became concerned. In 2016 and again in 2017, the PSA level was about six times what it had been the year before. My doctor at Duke agreed that I should be concerned and recommended that I have the PSA test repeated at Duke. I had this done there on May 23 [point 6], and the result was 1.93, even higher than it had been the month before. (Results from different labs are not necessarily comparable.) At this visit to Duke, I also consulted with a radiation oncologist, who suggested that I was probably going to want to do something about this "biochemical recurrence" of prostate cancer. Cancerous cells had evidently escaped from my prostate before surgery after all. None of the suggested treatment options seemed pleasant to me.

PSA doubling time (how long it takes one's PSA level to double) is considered a measure of how aggressive the cancer is. If it is very slow, say a year or more, the problem might be ignored by someone my age (70 in June). I wanted to see a medical oncologist for a second opinion. Perhaps like many men, I considered hormone therapy and any form of castration, chemical or otherwise, to be obnoxious, an absolute last resort. I returned to Duke on June 16 for the desired second opinion of a highly qualified medical oncologist. We agreed to wait on beginning treatment, since my PSA was still rather low. He wanted me to come back for a bone scan and another PSA test in about three months to get a better handle on how aggressive my cancer is. He calculated my PSA doubling time then to be 4.9 months, which he considered indicative of fairly aggressive growth of the cancer.

Not long after the visit to Duke in June, I let Dr. Aardsma know about my condition, and he immediately suggested trying MePA to see whether it might help improve my condition. At first, I tried to buy MePA on the open market but discovered that it is sold to research organizations and educational institutions only. It could not be shipped to a private residence. Fortunately, Dr. Aardsma graciously supplied me with a dropper bottle of his vitamin MePA dietary supplement, and I started using it on July 17. For the first six days, my dose rate was 2 micrograms per day. Ever since then, with his assent, it has been 4 micrograms per day.

After I started taking MePA and while waiting for my September appointment at Duke, I was already in good health and did not notice any remarkable change in my health, with only one or two possible exceptions. When I went to see the solar eclipse in August, I got sunburned, and I was surprised that it did not hurt at all. I also suspect some improvement in healing time. I accidentally jabbed a sharp stick into the palm of my hand. Today, less than four weeks later, the wound is barely detectable as a faint scar.

The "acid test" of MePA came on September 27, when I returned to Duke for the bone scan and my most recent PSA test. (My bone scan raised no concerns, but this result was expected.) If my PSA doubling time had remained steady, then my PSA level would have been at about 2.5 when I started taking MePA, and it should have risen to about 3.5 by the date of this test. Those projected levels could have been even higher, depending on the data points selected for inclusion in the calculation of doubling time.

I was amazed by the new result, which was only 2.31, well below the expected level, even with a conservative doubling time.

Dr. Aardsma provided the chart above to illustrate. The black line plots my rising PSA level (either measured or extrapolated), the vertical red line marks the date of my first dose of MePA, and the pink dot at the right edge [point 7] marks my unexpected PSA test result (2.31). Each date at the bottom is 200 days before or after an adjacent date. Of course, PSA levels are indicated at the left edge. My oncologist was evidently less amazed than I was. He explained that the doubling time can vary when the PSA level is still this low, but we agreed that there was no need for me to begin treatments right away. He wanted me to come back for another PSA test and consultation in about three months.

Regardless of my doctor's expert opinion, I am delighted and thankful, not only to Dr. Aardsma but also to God and to those who prayed for me. After all, it was ultimately God who left us reliable life span data in Genesis and gifted Dr. Aardsma with the faith, patience, intelligence, determination, and whatever else may have been needed to take enough advantage of the information provided to discover vitamin MePA. Nevertheless, not even this matches God's wonderful grace and the gift of eternal salvation to me and anyone else who will receive it (John 3:16; Rev. 22:16-17).

The latest PSA result suggests that my system has been significantly rejuvenated, allowing it to fight off cancer cells, wherever they may be in my body, especially in light of the fact that the level of MePA in my system, though slowly rising, may still be well below the optimum level. Of course, the results of my next PSA test, currently scheduled for early January, should be even more enlightening with regard to my future prospects for full recovery from prostate cancer. In the meantime, I am continuing to take MePA without any other form of cancer therapy.

If MePA can cure Dr. Aardsma's case of CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) and my biochemical recurrence of prostate cancer, then it offers everyone with a similar medical condition considerable hope of dramatic improvements in health at low cost and in a short amount of time. Obviously, it would take hundreds of years to prove that MePA can allow someone to live to be hundreds of years old. Anyone waiting for this proof may wait too long and never receive any benefit, but MePA should still be attractive if it really does provide significant improvement in quality of life now. Please see Helen Aardsma's personal testimonial in Aging: Cause and Cure for a case where a significant health benefit has been noticed even though no serious medical condition was involved.

Anecdotal evidence like mine should be considered less reliable than formal clinical studies, of course, but at this stage, even this kind of evidence should be of interest. Not counting the fascinating theory behind Dr. Aardsma's discovery, this is still the best evidence of MePA effectiveness that can be offered at this time. As usual, your results may vary.


by Gerald Aardsma; July 10, 2018

Tom's PSA continues to be monitored on a regular basis by his health care professionals. The table and graph below show the latest results.


Error bars (1σ) have been added to the graph to help visualize the scatter in the data points.

The black line is the best-fit exponential growth curve for the data points up until Tom started taking Dr. Aardsma's Vitamin MePA Dietary Supplement. The blue line is the best-fit exponential growth curve for the entire dataset.

It is clear that progression of Tom's cancer has been slower since he started taking vitamin MePA than it was predicted to be before he started taking the vitamin. It is still far from certain, however, that this outcome is due to the vitamin. The uncertainties in the measured data points, shown by the error bars, are relatively large. These uncertainties arise because of biological fluctuations in PSA from day to day. These large uncertainties make it possible that Tom's pre-MePA measurements just happened to come out high by chance.

As Tom stated above, improved reliability can be obtained from a clinical trial involving many test individuals. The present pilot study on Tom encourages the undertaking of such a clinical trial.

Meanwhile, notice that what we are not seeing here is a rapid cure of prostate cancer by vitamin MePA. This emphasizes that the best strategy is to take the vitamin faithfully every day while one is still youthful, to prevent aging related diseases from ever getting started.

  Copyright © 2018 Aardsma Research & Publishing. All rights reserved.